natgillin/translations-raw huggingface dataset:
Talk to your doctor or pharmacist before using Oslif Breezhaler if you have asthma (in this case you should not use Oslif Breezhaler). 
Obratite se svom liječniku ili ljekarniku prije nego primijenite Oslif Breezhaler ako imate astmu (u tom slučaju ne biste trebali koristiti Oslif Breezhaler). ako imate problema sa srcem.
This opens the inhaler. 
To otvara inhalator.
The 24-hour bronchodilator effect of Oslif Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis). 
Bronhodilatacijski 24-satni učinak Oslif Breezhalera bio je zadržan od prve doze kroz jednogodišnje razdoblje liječenja bez dokaza gubitka djelotvornosti (tahifilaksija).
In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5), which may increase the susceptibility to cardiac arrhythmias. 
U bolesnika s teškim KOPB-om hipokalijemija može biti potencirana hipoksijom i istodobno primijenjenim lijekovima (vidjeti dio 4.5), što može povećati osjetljivost za srčane aritmije.
In clinical studies which included urine collection, the amount of indacaterol excreted unchanged via urine was generally lower than 2% of the dose. 
U ispitivanjima koja su uključivala sakupljanje mokraće, količina indakaterola koja se izlučila nepromijenjena u mokraću u pravilu je bila manja od 2% doze.
In vitro investigations indicated that UGT1A1 is the only UGT isoform that metabolised indacaterol to the phenolic O-glucuronide. 
In vitro istraživanja su pokazala da je UGT1A1 jedina UGT izoforma koja je metabolizirala indakaterol do fenolnog O-glukuronida.
Beta-adrenergic blockers and beta2-adrenergic agonists may weaken or antagonise the effect of each other when administered concurrently. 
Beta-adrenergički blokatori i beta2-adrenergički agonisti mogu oslabiti ili djelovati antagonistički na učinak jedni drugima kada se istodobno primjenjuju.
Use of cardioselective beta blockers may be considered, but only under the supervision of a physician and with extreme caution since the use of beta-adrenergic blockers may provoke bronchospasm. 
Treba razmotriti primjenu kardioselektivnih beta blokatora, ali samo uz liječnički nadzor i uz krajnji oprez, jer primjena beta-adrenergičkih blokatora može izazvati bronhospazam.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu 
Ostali izvori informacija Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu
Inhibition of the key contributors of indacaterol clearance, CYP3A4 and P-glycoprotein (P-gp) raises the systemic exposure of indacaterol by up to two-fold. 
Inhibicija ključnih čimbenika koji pridonose klirensu indakaterola, CYP3A4 i P-glikoprotein (P-gp), podiže sistemsku izloženost indakaterola do dva puta.
Prepare capsule: 
Pripremite kapsulu:
These studies included measures of lung function and of health outcomes such as dyspnoea, exacerbations and health-related quality of life. 
Ta su ispitivanja uključivala mjerenja plućne funkcije i zdravstvenih ishoda kao što su dispneja, egzacerbacije i kvaliteta života vezana za zdravlje.
If you have questions about how long to continue your treatment with Oslif Breezhaler, talk to your doctor or pharmacist. 
Ako imate pitanja o tome koliko dugo trebate provoditi liječenje Oslif Breezhalerom, obratite se svom liječniku ili ljekarniku.
If you use more Oslif Breezhaler than you should If you have inhaled too much Oslif Breezhaler or if someone else uses your capsules, tell your doctor immediately or go to the nearest emergency unit. 
Ako ste udahnuli previše Oslif Breezhalera ili ako je netko drugi koristio Vaše kapsule, morate odmah obavijestiti svog liječniku ili otići u najbližu jedinicu hitne pomoći.
Indacaterol is a partial agonist at the human beta2-adrenergic receptor with nanomolar potency. 
Indakaterol je dijelom agonist ljudskog beta2-adrenergičkog receptora s nanomolarnom snagom.
Indacaterol was excreted into human faeces primarily as unchanged parent substance (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose). 
Indakaterol se izlučivao ljudskom stolicom ponajprije kao nepromijenjena izvorna tvar (54% doze) te, u manjem dijelu, kao hidroksilirani metabolit indakaterola (23% doze).
As with other inhalation therapy, administration of Oslif Breezhaler may result in paradoxical bronchospasm that may be life-threatening. 
Kao i kod drugih inhalacijskih terapija, primjena Oslif Breezhalera može dovesti do paradoksalnog bronhospazma koji može ugroziti život.
Do not blow into the mouthpiece. 
Nemojte puhati u nastavak za usta.
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Oslif Breezhaler at the recommended doses than on placebo. 
Tijekom ispitivanja, klinički značajne promjene glukoze u krvi u pravilu su bile češće za 1-2% pri primjeni Oslif Breezhalera u preporučenim dozama nego pri primjeni placeba.
Cough is a common symptom in COPD. 
Kašalj je česti simptom KOPB-a.
Occasionally, very small pieces of the capsule can get past the screen and enter your mouth. 
Komadići kapsule mogu povremeno proći kroz rešetku i ući Vam u usta.
When you inhale it, it relaxes the muscles in the walls of the small air passages in the lungs. 
Kada ga udahnete, on opušta mišiće u stijenkama dišnih puteva u plućima.
As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Oslif Breezhaler treatment and those patients who received placebo or treatment with tiotropium. 
Kao što je pokazano u 605 bolesnika s KOPB-om u dvostruko slijepom, placebo kontroliranom ispitivanju faze III u trajanju od 26 tjedana, nije bilo klinički značajne razlike u razvoju aritmičkih događaja praćenih tijekom 24 sata, na početku i do 3 puta tijekom razdoblja liječenja od 26 tjedana, između bolesnika koji bili liječeni preporučenim dozama Oslif Breezhalera i onih koji su primali placebo ili bili liječeni tiotropijem.
• Close the inhaler. 
• Zatvorite inhalator.
Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassiumsparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution is required (see section 4.4). 
Istodobno liječenje lijekovima koji mogu uzrokovati hipokalijemiju, tj. derivatima metilksantina, steroidima ili diureticima koji ne štede kalij može potencirati mogući hipokalijemički učinak beta2adrenergičkih agonista, pa je zato potreban oprez (vidjeti dio 4.4).
INNER LID OF OUTER CARTON OF UNIT PACK AND OF INTERMEDIATE CARTON OF MULTIPACK 
UNUTARNJI POKLOPAC VANJSKE KUTIJE JEDINIČNOG PAKIRANJA I SREDNJE KUTIJE VIŠESTRUKOG PAKIRANJA
The pharmacological effects of beta2-adrenoceptor agonists are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cyclic monophosphate). 
Farmakološki učinci beta2-adrenoceptorskih agonista mogu se barem djelomično pripisati stimulaciji unutarstanične adenil ciklaze, enzima koji katalizira konverziju adenozin trifosfata (ATP) u ciklički3', 5'-adenozin monofosfat (ciklički monofosfat).
Oslif Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo. 
Dokazano je da Oslif Breezhaler smanjuje plućnu hiperinflaciju, što dovodi do povećanog kapaciteta udisanja tijekom vježbe i u mirovanju, u usporedbi s placebom.
Concomitant administration of other sympathomimetic medicinal products (alone or as part of combination therapy) may potentiate adverse reactions to Oslif Breezhaler. 
Istodobna primjena drugih simpatomimetičkih lijekova (samih ili u kombiniranom liječenju) može potencirati nuspojave Oslif Breezhalera.
At 600 microgram once-daily, the safety profile of Oslif Breezhaler was overall similar to that of recommended doses. 
Pri dozi od 600 mikrograma jedanput na dan, sigurnosni profil Oslif Breezhalera u cjelini je bio sličan onom pri preporučenim dozama.
The effective half-life, calculated from the accumulation of indacaterol after repeated dosing ranged from 40 to 52 hours which is consistent with the observed time-to-steady state of approximately 12-14 days. 
Stvaran poluživot, izračunat iz nakupljanja indakaterola nakon ponovljenih doza, bio je u rasponu od 40 do 52 sata, što je u skladu sa zapaženim vremenom do stanja dinamičke ravnoteže od približno 12-14 dana.
• pain in muscles, bones or joints 
• bol u mišićima, kostima ili zglobovima
There was no evidence of a concentration-delta QTc relationship in the range of doses evaluated. 
Nema dokaza povezanosti koncentracije i delta QTc-a u rasponu ispitivanih doza.
An overdose of indacaterol is likely to lead to exaggerated effects typical of beta2-adrenergic stimulants, i.e. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia and hyperglycaemia. 
Predoziranje indakaterolom vjerojatno dovodi do pretjeranih učinaka karakterističnih za beta2adrenergičke stimulatore, tj. tahikardije, tremora, palpitacija, glavobolje, mučnine, povraćanja, pospanosti, ventrikularnih aritmija, metaboličke acidoze, hipokalijemije i hiperglikemije.
Therefore, long-acting beta2-adrenergic agonists such as Oslif Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval. 
Stoga, dugodjelujuće beta2adrenergičke agoniste kao što je Oslif Breezhaler treba oprezno koristiti u bolesnika s poznatim ili suspektnim produljenjem QT intervala ili u onih koji se liječe lijekom koji utječe na QT interval.
Percentage of patients who achieved MCID SGRQ† 
Postotak bolesnika koji su postigli MCID SGRQ
Systemic exposure to indacaterol increased with increasing dose (150 microgram to 600 microgram) in a dose proportional manner. 
Sistemska izloženost indakaterola rasla je proporcionalno s povećanjem doze (150 mikrograma do 600 mikrograma).
The capsules must be administered only using the Oslif Breezhaler inhaler (see section 6.6). 
Kapsule se moraju primjenjivati samo uz pomoć Oslif Breezhaler inhalatora (vidjeti dio 6.6).
Oslif Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists. 
Oslif Breezhaler ne treba koristiti zajedno s drugim dugodjelujućim beta2-adrenergičkim agonistima ili lijekovima koji sadrže dugodjelujuće beta2-adrenergičke agoniste.
There was a rapid onset of action within 5 minutes after inhalation, with an increase in FEV1 relative to baseline of 110-160 ml, comparable to the effect of the fast-acting beta2-agonist salbutamol 200 microgram and statistically significantly faster compared to salmeterol/fluticasone 50/500 microgram. 
Početak djelovanja bio je brz, unutar 5 minuta nakon inhalacije, uz povećanje FEV1-a u odnosu na početne vrijednosti od 110-160 ml, što je usporedivo s učinkom brzodjelujućeg beta2-agonista salbutamola u dozi od 200 mikrograma te statistički značajno brže u usporedbi sa salmeterolom/flutikazonom u dozi od 50/500 mikrograma.
In vitro studies have shown that indacaterol, a long-acting beta2-adrenergic agonist, has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3receptors. 
In vitro ispitivanja pokazala su da indakaterol, dugodjelujući beta2-adrenergički agonist, ima više od 24 puta veće agonističko djelovanje na beta2-receptore u usporedbi s beta1-receptorima te 20 puta veće agonističko djelovanje u usporedbi s beta3-receptorima.
Paediatric population There is no relevant use of Oslif Breezhaler in the paediatric population (under 18 years). 
Nema relevantne primjene Oslif Breezhaler u pedijatrijskoj populaciji (mlađih od 18 godina).
How to clean your inhaler 
Kako čistiti svoj inhalator
Indacaterol once a day 
Indakaterol jedanput na dan
These include: o steroids (e.g. prednisolone), o diuretics (water tablets) used for high blood pressure such as hydrochlorothiazide, o medicines for breathing problems such as theophylline. 
To uključuje: o steroide (npr. prednizolon), o diuretike (tablete za mokrenje) kao što je hidroklorotiazid, koji se koriste kod visokog krvnog tlaka, o lijekove za probleme s disanjem kao što je teofilin.
Systemic exposures (AUC) in rats and mice at the no-observed adverse effect levels in these studies were at least 7- and 49-fold higher, respectively, than in humans treated with Oslif Breezhaler once a day at a dose of 300 microgram. 
Sistemska izloženost (AUC) na razinama na kojima nisu bile zapažene nuspojave u ovim je ispitivanjima u štakora i miševa bila najmanje 7, odnosno 49 puta veća od one u ljudi liječenih Oslif Breezhalerom jedanput na dan u dozi od 300 mikrograma.
Increased incidences of benign ovarian leiomyoma and focal hyperplasia of ovarian smooth muscle in rats were consistent with similar findings reported for other beta2-adrenergic agonists. 
Povećana incidencija dobroćudnog lejomioma jajnika i fokalne hiperplazije glatkog mišića jajnika u štakora bila je u skladu sa sličnim nalazima prijavljenim za druge beta2-adrenergičke agoniste.
To breathe the medicine deeply into your airways: 
Kako biste udahnuli lijek duboko u dišne puteve:
Oslif Breezhaler is a long-acting beta2-adrenergic agonist, which is only indicated for COPD and should not be used in asthma due to the absence of long-term outcome data in asthma. 
Oslif Breezhaler je dugodjelujući beta2-adrenergički agonist koji je indiciran samo za KOPB i ne treba se koristiti u astmi jer nema podataka o ishodima pri dugotrajnoj primjeni u astmi.
The European Medicines Agency has waived the obligation to submit the results of studies with Oslif Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Oslif Breezhalera u svim podskupinama pedijatrijske populacije s kroničnom opstruktivnom plućnom bolešću (KOPB) (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Oslif Breezhaler at recommended therapeutic doses (see section 5.1). 
Klinički važni učinci produljenja QTc-intervala nisu bili zapaženi u ispitivanjima Oslif Breezhalera u preporučenim terapijskim dozama (vidjeti dio 5.1).
In addition, patients treated with Oslif Breezhaler required significantly less rescue medication, had more days when no rescue medication was needed compared to placebo and had a significantly improved percentage of days with no daytime symptoms. 
Osim toga, bolesnici liječeni Oslif Breezhalerom trebali su značajno manje lijekova za hitno ublažavanje simptoma, imali su više dana bez lijekova za hitno ublažavanje simptoma u usporedbi s placebom te su imali značajno povećanje postotka dana bez dnevnih simptoma.
Wipe the mouthpiece inside and outside to remove any powder with a clean, dry lint-free cloth. 
Obrišite nastavak za usta iznutra i izvana čistom, suhom tkaninom kako biste odstranili ostatak praška.
Like other beta2-adrenergic agonists, indacaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms. 
Kao i ostali beta2-adrenergički agonisti, indakaterol može proizvesti klinički značajan kardiovaskularni učinak u nekih bolesnika kao što je povećanje pulsa, krvnog tlaka i/ili drugih simptoma.
Formoterol twice a day 
Formoterol dva puta na dan
• if you get irregular heart beat (uncommon). 
• ako imate nepravilne otkucaje srca (manje često)
The powder in the capsules is for you to inhale. 
Prašak u kapsulama namijenjen je inhaliranju.
Of these patients, 2,611 were on treatment with 150 microgram once daily and 1,157 on treatment with 300 microgram once daily. 
2611 od tih bolesnika bilo je liječeno dozom od 150 mikrograma jedanput na dan, a 1157 dozom od 300 mikrograma jedanput na dan.
c: indacaterol 300 microgram, formoterol and placebo MCID = minimal clinically important difference (≥1 point change in TDI, ≥4 point change in SGRQ) n/e= not evaluated at six months 
MCID = najmanja klinički važna razlika (≥1 boda promjene u TDI-u, ≥4 boda promjene u SGRQ-u) n/p = nije procijenjeno u šest mjeseci
Oslif Breezhaler has no or negligible influence on the ability to drive and use machines. 
Oslif Breezhaler ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
What Oslif Breezhaler is and what it is used for What you need to know before you use Oslif Breezhaler How to use Oslif Breezhaler Possible side effects 
Što je Oslif Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Oslif Breezhaler Kako primjenjivati Oslif Breezhaler Moguće nuspojave
In COPD the muscles around the airways tighten. 
U KOPB-u se mišići oko dišnih puteva stežu.
Oslif Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators. 
Oslif Breezhaler sadrži djelatnu tvar indakaterol koja pripada skupini lijekova koji se nazivaju bronhodilatatori.
A double-blind, placebo- and active (moxifloxacin)-controlled study for 2 weeks in 404 healthy volunteers demonstrated maximum mean (90% confidence intervals) prolongations of the QTcF interval (in milliseconds) of 2.66 (0.55, 4.77) 2.98 (1.02, 4.93) and 3.34 (0.86, 5.82) following multiple doses of 150 microgram, 300 microgram and 600 microgram, respectively. 
Dvostruko slijepo, placebo i aktivno (moksifloksacinom) kontrolirano ispitivanje tijekom 2 tjedna u 404 zdrava dobrovoljca pokazalo je najveća srednja (90% intervali pouzdanosti) produljenja QTcF intervala (u milisekundama) od 2,66 (0,55, 4,77), 2,98 (1,02, 4,93) i 3,34 (0,86, 5,82) nakon višekratnih doza od 150 mikrograma, 300 mikrograma, odnosno 600 mikrograma.
After you have inhaled the medicine: 
Nakon što ste udahnuli lijek:
How long to continue your treatment with Oslif Breezhaler Keep using your treatment with Oslif Breezhaler for as long as your doctor tells you. 
Koliko dugo trebate nastaviti svoje liječenje Oslif Breezhalerom Nastavite svoje liječenje Oslif Breezhalerom toliko dugo koliko Vam je rekao liječnik.
If paradoxical bronchospasm occurs Oslif Breezhaler should be discontinued immediately and alternative therapy substituted. 
Ako dođe do pojave paradoksalnog bronhospazma, primjenu Oslif Breezhalera treba odmah prekinuti i zamijeniti ga drugim lijekom.
• if you have difficulty breathing with wheezing or coughing (uncommon). 
• ako imate otežano disanje s piskanjem pri disanju ili kašljem (manje često).
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Oslif Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2-adrenergic agonists. 
Iako nije bio zapažen klinički značajan učinak na kardiovaskularni sustav nakon primjene Oslif Breezhalera u preporučenim dozama, indakaterol treba, kao i druge beta2-adrenergičke agoniste, oprezno primjenjivati u bolesnika s kardiovaskularnim poremećajima (koronarna srčana bolest, akutni infarkt miokarda, srčane aritmije, hipertenzija), u bolesnika s konvulzivnim poremećajima ili tireotoksikozom te u bolesnika koji imaju neuobičajeni odgovor na beta2-adrenergičke agoniste.
Some people may occasionally cough briefly soon after inhaling the medicine. 
Neki ljudi mogu povremeno kašljati ubrzo nakon inhaliranja lijeka.
At the recommended doses, the adverse reaction profile of Oslif Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation. 
U preporučenim dozama profil nuspojava Oslif Breezhalera u bolesnika s KOPB-om pokazuje klinički beznačajne sistemske učinke beta2-adrenergičke stimulacije.
It is not harmful if these pieces are swallowed or inhaled. 
Neće Vam naškoditi ako ih progutate ili udahnete.
Oslif Breezhaler capsules must always be stored in the blister, and only removed immediately before use. 
Oslif Breezhaler kapsule se moraju uvijek čuvati u blisteru te se smiju izvaditi tek neposredno prije primjene.
Oslif Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies. 
Oslif Breezhaler primijenjen jedanput na dan u dozi od 150 i 300 mikrograma dosljedno je pružao klinički značajna poboljšanja plućne funkcije (mjereno forsiranim izdisajnim volumenom u jednoj sekundi, FEV1) tijekom 24 sata kroz brojna farmakodinamička ispitivanja i ispitivanja djelotvornosti.
In a human ADME study where indacaterol was given orally, the faecal route of excretion was dominant over the urinary route. 
U ADME ispitivanju u ljudi, kada je indakaterol bio davan oralno, stolica je bila dominantni put izlučivanja u odnosu na mokraću.
Like other beta2-adrenergic agonists, indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle. 
Kao i drugi beta2-adrenergički agonisti, indakaterol može inhibirati porod zbog učinka relaksacije na glatke mišiće maternice.
Immediate hypersensitivity reactions have been reported after administration of Oslif Breezhaler. 
Reakcije preosjetljivosti su odmah bile prijavljene nakon primjene Oslif Breezhalera.
Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl methacrylate acrylonitrile butadiene styrene. 
Tijelo inhalatora i poklopac su napravljeni od akrilonitril butadien stirena, tipke su napravljene od metil metakrilat akrilonitril butadien stirena.
• Place the mouthpiece in your mouth and close your lips firmly around it. 
• Stavite nastavak u usta i usnama ga čvrsto obujmite.
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Oslif Breezhaler. 
Iako indakaterol nije u pravilu utjecao na reproduktivne parametre u ispitivanju plodnosti u štakora, zapažen je pad broja trudnih F1 potomaka u ispitivanju peri- i post-razvoja u štakora pri izloženosti 14 puta većoj od one u ljudi liječenih Oslif Breezhalerom.
Indacaterol has not been shown to cause interactions with medicinal products administered concomitantly. 
Pokazano je da indakaterol ne ulazi u interakcije s istodobno primijenjenim lijekovima.
Treatment comparison compared to placebo showed a ratio of rates of 0.68 (95% CI [ 0.47, 0.98]; p-value 0.036) and 0.74 (95% CI [0.56, 0.96]; pvalue 0.026) for 150 microgram and 300 microgram, respectively. 
Usporedba s placebo grupom pokazala je omjer stopa od 0,68 (95% CI [ 0,47, 0,98]; p-vrijednost 0,036) i 0,74 (95% CI [0,56, 0,96]; p-vrijednost 0,026) za doze od 150 mikrograma, odnosno 300 mikrograma.
• Open the mouthpiece again, remove the empty capsule by tipping it out of the capsule chamber. 
• Ponovno otvorite nastavak za usta, odstranite praznu kapsulu naginjanjem iz komore za kapsulu.